Jul. 2022 – Issuance of U.S. Patent
River Stone Biotech Inc. Announces Issuance of U.S. Patent . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the issuance of a U.S. Patent covering a unique production technology for the preparation of Buprenorphine. The process is higher efficiency and uses more environmentally-friendly reagents than conventional production methods. This production approach is synergistic with RSB’s proprietary methods to produce alkaloid starting materials via fermentation in a cost-effective manner, as described in previously granted US Patent 11,060,071. U.S. Patent No. 11,390,628 is entitled “Preparation of buprenorphine“ and...
Apr. 2022 – Participation DCAT 2022
River Stone Biotech Inc. participates in DCAT 2022 . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the use of its transformational technology in the manufacture of buprenorphine and other n-demethylation products including naloxone and naltrexone. The novel patent-protected technology employed will allow reliable supply of these vital APIs at much superior value – both economically and environmentally – to those available in the market today. The technology employs a combination of state-of-the-art synthetic biology followed by other more traditional production methods; this novel...
Nov. 2021 – $6.8M Series B Financing
River Stone Biotech Inc. Announces $6.8M Series B Financing . Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Advance Lead Pipeline Projects To Treat Opiate Use Disorder and Opiate Overdose. – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the completion of a $6.8 million Series B financing. Led by an individual specialty healthcare investor, the financing included new investments from 5 private investors along with further participation from existing investor, Dick Cashin. In conjunction with the financing, James (Jeb) Besser, has...